Company Overview
Snapshot
Founded in September 2022 by Morris Laster, Tedence operates with 1–10 employees. The company is currently in the Pre-Funding stage and is developing an AI-powered therapeutic platform. In September 2023, Tedence was featured for its innovative approach to managing juvenile diabetes.
Business overview
Tedence is an AI-powered healthcare platform specializing in personalized therapeutic solutions for chronic and autoimmune diseases. The company's core technology involves utilizing artificial intelligence to create bioelectric treatments delivered through wearable technology. Tedence aims to address conditions such as diabetes, operating within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.
Strategic signal
In September 2023, Tedence gained recognition for its innovative development in addressing juvenile diabetes. This highlights the company's potential to leverage its AI-powered bioelectric treatments for specific chronic conditions, signaling a focused and impactful application of its technology within the health tech market.
Log in to access full profile ›Company Intelligence Q&A
- When was Tedence founded?
- Tedence was founded in September 2022 by Morris Laster.
- What is Tedence's primary focus?
- Tedence focuses on developing an AI-powered therapeutic platform for chronic and autoimmune diseases, utilizing bioelectric treatments delivered via wearable technology.
- What significant recognition did Tedence receive in 2023?
- In September 2023, Tedence was featured for its innovative development in addressing juvenile diabetes.
- Who is the founder of Tedence?
- Morris Laster is the founder and CEO of Tedence.
- What is the current product stage of Tedence?
- Tedence's product is currently in the Clinical Trial stage, indicating it is undergoing testing to evaluate its safety and efficacy before potential market release.